Exin Therapeutics
Precision genetic therapies targeting neural activity across disorders
We’re building a precision genetic therapy platform that targets neurological and neuropsychiatric disorders from a circuit-level perspective. Current approaches pursue single-gene fixes that only help small subsets of patients, leaving a multi-million patient population without effective treatment options.
Gene therapy opens the door to precisely modifying brain circuits. The problem is the elevated risk in neuroscience drug discovery. To solve this, we use a pre-clinical screening platform, multiple gene therapy candidates, and ML analytics to develop gene therapies capable of controlling neural activity and addressing neurological conditions such as autism spectrum disorder, epilepsy, and Parkinson’s disease.
Active Founders
Ivan Lazarte, Founder
Experience in interdisciplinary research spanning Physics, Engineering and Neuroscience. DPhil in Physiology, Anatomy, and Genetics, focusing on molecular to systems level brain development and function, complemented by computational biophysical modeling.
Gabriel Ocana Santero, Founder
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Marko Tvrdic, Founder
Early, I worked as a molecular neuroscientist at Edinburgh University. I then got interested in neural activity and moved to start a PhD at Oxford. Now working to find new ways to cure disorders of the brain by fine-tuning neural activity.
YC Sign Photo
